Why Did Caribou Biosciences (Nasdaq:CRBU) Stock Plunge After Hours?

Caribou Biosciences Inc. (Nasdaq:CRBU) tumbled between about 35% and 46% in extended trading, to roughly $0.61 to $0.74 a share, after the gene-editing company said it would end development of both of its allogeneic CAR-T programs and cut a large part of its workforce. The announcement removed the clinical pipeline that had underpinned the equity story and left investors weighing a company that now looks more like a pile of cash than a drug developer.

The programs being dropped

Caribou will stop work on vispa-cel, which was being studied in relapsed or refractory B-cell non-Hodgkin lymphoma, and on CB-011, aimed at relapsed or refractory multiple myeloma. Both were allogeneic therapies, meaning they are built from donor cells and intended as off-the-shelf treatments rather than being engineered individually for each patient. That approach promised lower cost and faster delivery than conventional CAR-T, and it was the core of the company’s pitch to shareholders.

The staff reductions are large and will take place mostly in the fourth quarter. The company did not frame the decision as a pause. It described the end of further development for both candidates, which means the assets that supported the stock’s valuation are no longer part of the plan.

A strategic review with no deadline

The board has opened a review of strategic alternatives that could include a sale, a merger or another type of transaction. Wedbush is advising. Management set no timeline for the process and cautioned that a deal is not assured. For shareholders, that caveat matters: the review could end in a takeover, a combination with another company, an asset sale, or a return to a narrower business with far fewer employees.

Processes of this kind can run for months, and outcomes vary widely. Buyers of a company without a lead program are typically focused on cash, remaining intellectual property, and any platform technology that might be redeployed. Caribou has not said which of its assets, if any, it considers marketable beyond the two programs being wound down.

What the balance sheet shows

Cash and securities totalled $113.8 million at June 30. That is the main anchor for valuation now, though it is a figure from the end of the second quarter and does not reflect spending since then or the costs of the restructuring, including severance and any commitments tied to the discontinued trials. The eventual value available to shareholders will depend on how much of that cash is left when a transaction is struck and on what the market is prepared to pay for the remainder.

The share price, now below $1, adds another layer of pressure. Exchanges typically set a minimum bid price for continued listing, so a sustained period below that level can bring compliance notices and, in some cases, reverse stock splits. The company has not addressed that issue in the announcement.

Why the drop was so steep

Clinical-stage biotech stocks are priced largely on the possibility that a drug works. When the programs behind that possibility are withdrawn, the equity loses its growth premise at once. The after-hours decline of 35% to 46% reflects that repricing: the stock is moving from a development story to what traders call a cash-and-process situation, where the main question is how much cash survives and who might want the shell.

Extended-hours trading is thin, and moves can overshoot in either direction. The regular session on the next trading day will give a clearer read on where the stock settles.

What to watch next

Investors will look for details on the pace of layoffs, the cash burn through the fourth quarter, and any disclosure of interested parties. Any statement on remaining assets, patents or partnerships would also help determine whether the review can produce a premium or whether the stock will trade close to its cash value. Until then, the shares are likely to be driven by speculation about the outcome of the process rather than by science.